+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Corneal Neovascularization Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767571
  • Report
  • April 2019
  • Region: Global
  • 42 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Chiesi Farmaceutici SpA
  • Elman Retina Group PA
  • F. Hoffmann-La Roche Ltd
  • Laboratoires CTRS
  • Lux Biosciences Inc
  • Novartis AG
  • MORE
The global clinical trial report- “2019 Corneal Neovascularization Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Corneal Neovascularization. It presents in-depth analysis of Corneal Neovascularization clinical trials across markets and companies. The research work is for providing complete understanding into trends in Corneal Neovascularization.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Corneal Neovascularization clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Corneal Neovascularization

The research work is prepared through extensive and continuous research on Corneal Neovascularization trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Corneal Neovascularization patients are identified
  • The report includes panorama of Corneal Neovascularization clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Corneal Neovascularization clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Chiesi Farmaceutici SpA
  • Elman Retina Group PA
  • F. Hoffmann-La Roche Ltd
  • Laboratoires CTRS
  • Lux Biosciences Inc
  • Novartis AG
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Corneal Neovascularization Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Corneal Neovascularization Clinical Trials by Region
2.2.2 Average Enrollment of Corneal Neovascularization Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Corneal Neovascularization Treatment, 2019

3. Region wise Corneal Neovascularization Clinical Trials
3.1 Asia Pacific Corneal Neovascularization Clinical Trials by Country
3.2 Europe Corneal Neovascularization Clinical Trials by Country
3.3 North America Corneal Neovascularization Clinical Trials by Country
3.4 Middle East and Africa Corneal Neovascularization Clinical Trials by Country
3.5 South and Central America Corneal Neovascularization Clinical Trials by Country

4. Corneal Neovascularization Clinical Trial Trends
4.1 Start Year wise Corneal Neovascularization Clinical Trials
4.2 Phase wise Corneal Neovascularization Clinical Trials
4.3 Trial Status wise Corneal Neovascularization Clinical Trials
4.4 Trial Type wise Corneal Neovascularization Clinical Trials

5. Corneal Neovascularization Average Enrollment Trends
5.1 Average Enrollment in Corneal Neovascularization Trials by Year
5.2 Average Enrollment in Corneal Neovascularization Trials by Phase
5.3 Average Enrollment in Corneal Neovascularization Trials by Status
5.4 Average Enrollment in Corneal Neovascularization Trials by Type of Trial

6. Companies Participating in Corneal Neovascularization Clinical Trials
6.1 Corneal Neovascularization Trials by Sponsor Type
6.2 Corneal Neovascularization Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Corneal Neovascularization Trials- Phase 1
7.2 Corneal Neovascularization Trials- Phase 2
7.3 Corneal Neovascularization Trials- Phase 3
7.4 Corneal Neovascularization Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Corneal Neovascularization Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Corneal Neovascularization Clinical Trials and Enrolment
Figure 5: Europe - Country wise Corneal Neovascularization Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Corneal Neovascularization Clinical Trials and Enrolment
Figure 7: North America - Country wise Corneal Neovascularization Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Corneal Neovascularization Clinical Trials and Enrolment
Figure 9: Corneal Neovascularization Clinical Trials by Phase
Figure 10: Corneal Neovascularization Clinical Trials by Trial Status
Figure 11: Corneal Neovascularization Clinical Trials by Type
Figure 12: Corneal Neovascularization Clinical Trials by Sponsor Type
Figure 13: Corneal Neovascularization Clinical Trials by Leading Sponsors
Figure 14: Corneal Neovascularization Average Enrollment by Phase
Figure 15: Corneal Neovascularization Average Enrollment by Trial Status
Figure 16: Corneal Neovascularization Average Enrollment by Type
Figure 17: Corneal Neovascularization- Average Enrolment by Type of Sponsors
Figure 18: Corneal Neovascularization- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Corneal Neovascularization Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Corneal Neovascularization Clinical Trials and Enrolment
Table 5: Europe - Country wise Corneal Neovascularization Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Corneal Neovascularization Clinical Trials and Enrolment
Table 7: North America - Country wise Corneal Neovascularization Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Corneal Neovascularization Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Corneal Neovascularization Average Enrollment by Phase
Table 15: Corneal Neovascularization Average Enrollment by Trial Status
Table 16: Corneal Neovascularization Average Enrollment by Type
Table 17: Corneal Neovascularization- Average Enrolment by Type of Sponsors
Table 18: Corneal Neovascularization- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Chiesi Farmaceutici SpA
  • Elman Retina Group PA
  • F. Hoffmann-La Roche Ltd
  • Gene Signal International SA
  • Laboratoires CTRS
  • Lux Biosciences Inc
  • Novartis AG
  • Ohr Pharmaceutical Inc
  • Regeneron Pharmaceuticals Inc
  • Sisene Biotechnology
Note: Product cover images may vary from those shown
Adroll
adroll